GAGome for Bladder Cancer Risk

About Elypta

Elypta is an innovative diagnostics company developing a novel, metabolism-focused liquid biopsy platform centered on the GAGome. Its core technology uses mass spectrometry to quantify glycosaminoglycans in biofluids, with applications in multi-cancer early detection, recurrence monitoring for renal cell carcinoma, and risk stratification. The company is in the clinical validation and study phase, actively publishing data and engaging in large-scale European projects like PREDI-LYNCH, positioning itself in the high-growth liquid biopsy market.

Therapeutic Areas